Zuclopenthixol DecanoateThird Party Manufacturing in India

Zuclopenthixol Decanoate works by blocking central dopaminergic D1 and D2 receptors over an extended period. Deposition into muscle tissue as a fatty acid ester allows for slow, continuous enzymatic cleavage into active zuclopenthixol, maintaining stable plasma concentrations for 2 to 4 weeks. Unlike short-acting formulations, this depot delivery system prevents rapid spikes and drops in drug levels, ensuring continuous therapy for non-compliant patients. It is highly effective and well-tolerated for long-term management.

Therapeutic Uses

• Maintenance in Schizophrenia: Prevents relapses and manages chronic schizophrenic psychoses in patients with a history of non-compliance.
• Paranoid Psychoses: Suppresses long-term delusional states and associated chronic behavioral issues.

Why Manufacturers Choose Zuclopenthixol Decanoate

Investing in Zuclopenthixol Decanoate third party manufacturing in India provides a valuable asset for chronic mental health lines. Celesta Healthcare supports this niche segment by ensuring that our production facilities are WHO-GMP certified for processing viscous, sterile oil vehicle depots. This advanced processing keeps the active molecule under CAS number 85721-06-8 stable and free from impurities. Consistently manufacturing under strict WHO-GMP rules guarantees a smooth release profile, making it a reliable choice for institutional psychiatric supply chains.